Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
As the prevalence of diabetes mellitus is on the rise worldwide, the incidence of diabetic nephropathy (DN) increases. Unfortunately, the untreated DN is the most common cause of renal failure requiring renal replacement therapy. So, this book evaluate the renoprotective effect of aliskiren monotherapy and aliskiren-pentoxifylline combination, and to compare it with other renin-angiotensin system inhibitors as ACEIs and ARBs in hypertensive-diabetic type 2 patients with DN to reduce the development of DN into end stage renal disease.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
As the prevalence of diabetes mellitus is on the rise worldwide, the incidence of diabetic nephropathy (DN) increases. Unfortunately, the untreated DN is the most common cause of renal failure requiring renal replacement therapy. So, this book evaluate the renoprotective effect of aliskiren monotherapy and aliskiren-pentoxifylline combination, and to compare it with other renin-angiotensin system inhibitors as ACEIs and ARBs in hypertensive-diabetic type 2 patients with DN to reduce the development of DN into end stage renal disease.